Publication | Closed Access

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Hematological MalignancyOncologyTransplantationHematologyClinical TrialsImmunologyMyeloid NeoplasiaRadiation OncologyMedicineCell TransplantationHealth Sciences